Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools for improved treatment outcomes.
↧